Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival.
AffiliationClinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
MetadataShow full item record
AbstractIntroduction: Clinical markers to predict the benefit from sorafenib in patients diagnosed with hepatocellular carcinoma (HCC) are lacking. A meta-analysis exploring the impact of development of sorafenib-related side effects on survival was conducted. Areas covered: Eligible studies included all clinical studies reporting on the survival/toxicity relationship in sorafenib-treated HCC patients. Data sources included Pub-Med, the Cochrane Controlled Trials Register, and Google scholar. After exclusion of ineligible studies, 16 studies were included in the analysis. Pooled hazard ratio (HR) for overall survival (OS) for patients developing diarrhoea vs. patients who did not was 0.42 (95% confidence interval (CI): 0.30-0.60; p < 0.00001); pooled HR for patients developing hypertension vs. those who did not was 0.46 (95% CI: 0.30-0.70; p = 0.0003); pooled HR for patients developing hand foot skin reaction vs. those who did not was 0.47 (95% CI: 0.35-0.62; p < 0.00001); pooled HR for OS for all types of skin toxicities was 0.51 (95% CI: 0.36-0.72; p = 0.0002); while pooled HR for OS for a combination of selected side effects (hypertension, HFS and diarrhoea) was 0.38 (95% CI: 0.30-0.48; p < 0.00001). No information was available regarding the impact of thyroid dysfunction or proteinuria. Expert commentary: This analysis of data demonstrated that the occurrence of sorafenib-related side effects (such as diarrhoea, hypertension and skin toxicities) is associated with a better OS in sorafenib-treated HCC patients.
CitationDevelopment of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival. 2017, 11 (1):75-83 Expert Rev Gastroenterol Hepatol
JournalExpert Review of Gastroenterology & Hepatology
- Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
- Authors: Yada M, Masumoto A, Motomura K, Tajiri H, Morita Y, Suzuki H, Senju T, Koyanagi T
- Issue date: 2014 Sep 21
- Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis.
- Authors: Wang P, Tan G, Zhu M, Li W, Zhai B, Sun X
- Issue date: 2018 Jan
- Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review.
- Authors: Zhang X, Yang XR, Huang XW, Wang WM, Shi RY, Xu Y, Wang Z, Qiu SJ, Fan J, Zhou J
- Issue date: 2012 Oct
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem.
- Authors: Ziogas DC, Papadatos-Pastos D, Thillai K, Korantzis I, Chowdhury R, Suddle A, O'Grady J, Al-Khadimi G, Allen N, Heaton N, Ross PJ, Sarker D
- Issue date: 2017 Jan
- mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
- Authors: Meyer T, Palmer DH, Cheng AL, Hocke J, Loembé AB, Yen CJ
- Issue date: 2017 Jul